Abrupt Discontinuation of Buprenorphine and Risk of Psychosis: Clinical Considerations

This post is inspired by a real case from my practice involving a patient with no significant past psychiatric history but a strong history of substance use, including opioids and cocaine. The patient had been on buprenorphine maintenance therapy for several decades, providing stability in their recovery. However, following an abrupt discontinuation of buprenorphine, the patient developed acute psychotic symptoms. This case highlights an uncommon but important phenomenon clinicians should be aware of when managing buprenorphine discontinuation, especially in individuals with a history of substance use.

Emerging evidence suggests that abrupt discontinuation of buprenorphine may induce psychosis in some individuals, though this appears to be a relatively uncommon occurrence. Here are the key findings:

Documented Cases

• New-onset psychotic symptoms have been reported after sudden cessation of buprenorphine in patients with no prior psychosis.
• Common symptoms include auditory hallucinations, paranoid ideation, and delusions of reference.
• Psychotic symptoms typically emerge within days to weeks after discontinuation.

Potential Mechanisms

1. Loss of buprenorphine’s antipsychotic effects through kappa-opioid receptor antagonism.
2. Interaction between neurobiological vulnerabilities and the stress of withdrawal.
3. Possible unmasking of latent psychotic disorders.

Risk Factors

• History of substance use.
• Early adverse life events.
• Underlying psychiatric conditions (e.g., bipolar disorder).

Outcomes and Management

• Symptoms may resolve in weeks to months, though some cases persist longer.
• Reintroduction of buprenorphine has led to symptom remission in some cases, suggesting a causal relationship.
• Gradual tapering of buprenorphine might mitigate this risk, though more research is needed.

Clinical Implications

Clinicians should remain vigilant when discontinuing buprenorphine, especially in individuals with risk factors for psychosis. A gradual tapering strategy is recommended to reduce potential risks, though further studies are necessary to guide best practices.

Understanding this phenomenon highlights the importance of individualized care when managing buprenorphine discontinuation in vulnerable populations.